
    
      Study Design:

      Part A evaluated ANA773 following oral administration to healthy volunteers. A total of 40
      evaluable healthy volunteers were enrolled in Part A of the study.

      Part B evaluated ANA773 following oral administration to patients with chronic HCV infection.
      A total of 34 evaluable patients were enrolled in Part B of this study in 2 study centers.
    
  